Total trials
1,375
Active
123
Phase 3
354
Total enrollment
5,107,202
Pipeline matrix
Showing 40 of 60 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Semaglutide | — | 182 | |||||
| Insulin icodec | — | 32 | |||||
| Basal insulin analogues | — | — | — | — | — | 1 | |
| eptacog alfa | — | 23 | |||||
| Cagrilintide | — | — | — | 29 | |||
| NNC0487-0111 | — | — | — | 18 | |||
| somapacitan | — | — | 20 | ||||
| CagriSema | — | — | — | 8 | |||
| Concizumab | — | — | 9 | ||||
| Ziltivekimab | — | — | — | 7 | |||
| Oral semaglutide | — | — | — | 26 | |||
| Norditropin® | — | — | — | — | 4 | ||
| NNC6019-0001 | — | — | — | — | 3 | ||
| Zenagamtide | — | — | — | — | — | 2 | |
| liraglutide | — | 116 | |||||
| insulin glargine | — | — | 80 | ||||
| Etavopivat | — | — | — | 7 | |||
| Tirzepatide | — | — | — | — | 4 | ||
| Mim8 | — | — | — | — | — | 2 | |
| Ziltivekimab B | — | — | — | — | 2 | ||
| Ziltivekimab C | — | — | — | — | 2 | ||
| Ziltivekimab Placebo | — | — | — | — | — | 1 | |
| Etavopivat A | — | — | — | — | — | 1 | |
| Etavopivat B | — | — | — | — | — | 1 | |
| Etavopivat C | — | — | — | — | — | 1 | |
| insulin aspart | — | 137 | |||||
| NNC0662-0419 | — | — | — | — | 6 | ||
| CDR132L | — | — | — | — | 3 | ||
| Semaglutide placebo | — | — | — | — | 5 | ||
| UBT251 | — | — | — | — | — | 2 | |
| NNC0519-0130 | — | — | — | — | 10 | ||
| NNC0662-0419 Placebo | — | — | — | — | — | 1 | |
| UBT251 Placebo | — | — | — | — | — | 1 | |
| Cagrilintide D | — | — | — | — | — | 2 | |
| Cagrilintide B | — | — | — | — | — | 2 | |
| NNC0194-0499 | — | — | — | — | 10 | ||
| NNC0442-0344 A | — | — | — | — | — | 3 | |
| NNC0537-1482 | — | — | — | — | — | 2 | |
| NNC0581-0001 | — | — | — | — | — | 2 | |
| Oral contraceptive | — | — | — | — | — | 2 |
20 more active programs hidden
Next readouts
- 2021-05-05
- 2021-12-27
- 2022-07-12
- 2023-08-01
- 2024-06-07
- 2024-08-05
- 2024-10-30
- 2025-10-15
- 2026-02-01
- 2026-03-26
Top conditions
- Diabetes635
- Diabetes Mellitus, Type 2596
- Diabetes Mellitus, Type 1223
- Obesity172
- Healthy127
- Congenital Bleeding Disorder87
- Overweight71
- Haemophilia A63
Frequently asked questions about Novo Nordisk A/S
- How many clinical trials does Novo Nordisk A/S have on ClinicalTrials.gov?
- Novo Nordisk A/S is listed as the lead sponsor on 1,375 clinical trials in ClinicalTrials.gov, 123 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Novo Nordisk A/S's trials are in Phase 3?
- 354 of Novo Nordisk A/S's trials are in Phase 3, spread across 60 active drug programs.
- What therapeutic areas does Novo Nordisk A/S focus on?
- Novo Nordisk A/S's most-studied conditions on ClinicalTrials.gov are Diabetes, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Obesity, Healthy.
- When are Novo Nordisk A/S's next clinical trial readouts?
- Novo Nordisk A/S has 10 upcoming primary-completion readouts tracked here; the soonest is “A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day”, expected around 2021-05-05.